Encouraging results of EPO from basic research support the possibility of integrating its therapeutic effects in glaucomatous optic neuropathy, optic neuritis, non-arteritic anterior ischemic optic neuropathy (NAION), and traumatic optic neuropathy (TON). This evidence concerns the gene EPO and optic neuritis.